gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin expans vivo crispr trial
highlight week juli juli buy chardan top pick announc
collabor neurimmun ag privat develop vector antibodi vab neurodegen diseas
separ announc unpartn vab program hereditari angioedema believ
optim vab platform could mid- long-term make compani ideal partner big biopharma
advanc proven investig mab use aav vector edita medicin buy allergan unrat announc
initi brillianc phase i/ii trial vivo crispr therapi also
call leber congenit amaurosi edita allergan expect patient dose
trial set becom vivo crispr-bas gene edit therapi dose
human gensight biolog neutral report due manufactur readi time regulatori
file gene therapi gt leber hereditari optic neuropathi lhon push back
beyond compani state cash runway unrat announc interim
data transpher phase i/ii trial gt mucopolysaccharidosi type
iiia mp iiia across cohort dose-depend sustain reduct cerebrospin fluid csf heparan
sulfat report lower limit quantit reach patient cohort chardan initi
coverag replimun buy rate pt base potenti hsv-base oncolyt viru ov pipelin
boost respons immun checkpoint inhibitor rang solid tumor indic
look forward juli august compani report result unrat juli
unrat august et unrat august et
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
gene express new car-t take bite along ride tackl gbm
car-t shown impress efficaci blood cancer solid tumor applic challeng due
heterogen target antigen express within tumor express target antigen normal tissu rais
concern regard on-target off-tumor toxic bi-specif cell engag bite technolog design
simultan bind patient cell tumor cell promot tumor kill similar constraint
technolog typic seen compet strategi treat cancer
juli studi publish natur describ new dual car-t bite strategi circumv tumor
heterogen issu well-character target glioblastoma gbm without induc notabl toxic mous
model approach use car-t target egfrviii variant epiderm growth factor receptor egfr
present absent normal cell car-t target antigen describ
becom ineffect egfrviii lost advanc current studi construct addit encod
bite target normal egfr bite secret car-t low level gbm cell lose egfrviii
typic retain high express normal egfr enabl target bite intracrani inject cell
carri cart bite construct mice led complet respons cell
posit egfrviii variant engag deliv car-t cell brain target egfr cell bite
also engag non-transduc bystand cell kill egfr tumor cell importantli egfr express
mani tissu cart bite caus signific toxic skin graft model even upon system administr
suggest low level bite secret enabl preferenti target tumor cell over-express antigen target
pleas refer import disclosur inform regul analyst certif found page report
minim toxic normal cell howev clinic studi need determin actual safety/efficaci profil
cart bite potenti tumor type
approach repres sever strategi develop extend car-t activ solid tumor other
highlight april summari american associ cancer research meet includ
logic gate addit synthet biolog approach increas tumor/norm discrimin promot cell
function immunosuppress tumor microenviron
initi buy replic improv upon prior ov success juli livshit
initi coverag replimun buy rate base potenti hsv-base oncolyt viru
ov pipelin boost respons immun checkpoint inhibitor rang solid tumor indic
replimun pipelin contain asset deliv immune-stimulatori transgen compani lead asset
current phase i/ii trial cancer type alon combin agent
registration-direct random phase ii studi cutan squamou cell carcinoma expect begin soon
compani asset slate enter clinic quarter
base similar vector transgen unrat imlyg notabl improv imlyg
approv fda melanoma replimun manag involv initi develop
serv partli de-risk replimun pipelin use platform respect safeti
promis data imlyg combin checkpoint inhibitor us posit read-across efficaci
sight neutral file delay manufactur concern juli amusa
gensight report result provid updat regulatori pathway gensight end
mm cash manag guid cash suffici fund activ significantli
due concern manufactur readi time regulatori file gt
lhon push back beyond compani state cash runway
sinc issu uncommon aav-bas gene therapi gt space yet read much
delay monitor issu close given impact manufactur decis
cash burn see increas risk sharehold dilut address manufactur readi
note guid file consist time realiti natur histori studi may
address regulatori concern
mdco buy orion phase data near idmc review juli amusa
medicin compani chardan top pick report result provid updat rnai
therapeut inclisiran manag guid cash last phase data
readout nda/maa submiss well manufactur valid pre-commerci work
importantli mdco report idmc recommend continu inclisiran phase trial complet
plan un-blind data review time review substanti random patient treat
dose inclisiran placebo on-going review show materi safeti issu emerg data
least favor gener phase open label extens studi
mdco present dataset sequenti pivot phase trial inclisiran follow nda/maa
submiss septemb european societi cardiolog esc congress pari mdco
present data phase trial
buy enrol begin landmark vivo crispr trial juli livshit
edita medicin allergan unrat announc initi brillianc phase i/ii trial
vivo crispr therapi edita allergan expect patient dose
trial set becom crispr-bas gene edit therapi dose human
edita run prospect natur histori trial patient popul expect data
studi use inform design intervent studi note number outcom measur
phase i/ii trial align use proqr buy phase i/ii studi rna
oligonucleotide-bas therapeut sepofarsen patient mutat
buy lt posit possibl vector ab pipelin expans juli amusa
announc expans intern pipelin via collabor neurimmun ag privat
develop vector antibodi vab neurodegen diseas separately-announc vab program
us optim vector antibodi platform could make ideal
partner big biopharma advanc proven investig monoclon antibodi use aav vector
page
neurimmun collabor neurimmun jointli develop commerci vab
use technolog platform neurimmun revers translat medicin rtm human-
deriv antibodi platform first target tauopathi compani provid updat program
collabor advanc find sound logic aav-bas gt approach may provid
advantag enabl treatment tissu difficult deliv suffici amount therapeut antibodi
program use aav vector carri transgen encod antibodi plasma kallikrein
us valid approach given fda approv takhzyro august pipelin
expans may directli build upon experi wet use
vector deliv gene encod ranibizumab-lik anti-vegf monoclon antibodi fragment fab
genet medicin news juli juli
usc post preprint outlin inabl reproduc aav gene edit result unrat studi juli
xcur buy announc appoint jeffrey cleland timothi walbert board director juli
broad institut publish phage-assist continu evolut base editor bepac juli
vblt neutral receiv eu gmp complianc certif adenoviru manufactur facil juli
adap unrat announc initi radiat sub-studi spear cell tx juli
pact pharma privat present data neoantigen-specif cell captur juli
mgh publish cart bite cell target glioblastoma-specif tumor antigen juli
apic privat receiv fda orphan drug design aav-bas gt al juli
ucsd publish immune-orthogon orthologu aav evad immun respons juli
buy announc launch canada rnai tx onpattro hattr amyloidosi juli
agtc neutral complet enrol group pi/ii trial gt juli
ise neutral announc advanc minigen program new ird program juli
iver bio announc exercis option acquir enter global licens agreement
univers massachusett umass medic school right develop commerci aav-bas gt
leber congenit amaurosi type gt use minigen approach undisclos preclin data
result iver decis move program forward
iver also announc exclus agreement umass medic school develop commerci
aav-bas gt inherit retin diseas ird includ usher syndrom type
iver face competit buy allergan unrat announc week
initi phase i/ii trial vivo crispr therapi also call
well proqr buy develop rna therapeut sepofarsen ird iver face
competit edita preclin asset develop
unrat report result provid busi updat juli
rgl unrat announc program updat oligonucleotide-bas tx juli
regulu therapeut announc program updat oligonucleotide-bas therapeut
treatment autosom domin polycyst kidney diseas adpkd
juli regulu announc voluntarili paus phase clinic trial due unexpect
find mous chronic toxic studi run parallel phase trial complet
addit mous non-human primat nhp work submit result fda fda notifi regulu
addit nonclin data requir place ind partial clinic hold
order resum multipl ascend dose mad studi fda request final report mous
nhp studi well addit non-clin data analys gener next sever quarter
regulu may also proceed addit singl ascend dose sad studi supplement safeti data compil
previous complet sad studi
lonn-ch unrat report result highlight gt manufactur key sale driver juli
sickkid publish mutation-independ crispr activ treat mous model juli
nbse unrat announc appoint dr danith ly chief scientif offic juli
page
unrat receiv fda orphan drug design car-t tx aml juli
unrat announc appoint sath shukla chief offic juli
tscan tx privat launch mm fund cell receptor tcr tx platform juli
unrat announc appoint kri elverum svp busi develop strategi juli
adap unrat initi trial spear cell tx synovi sarcoma/mrcl juli
uc berkeley publish gene edit mous model huntington diseas juli
unrat announc interim data pi/ii trial gt mp iiia juli
abeona announc interim data transpher phase i/ii trial gt
mp iiia abeona pursu meet fda assess next step program
patient receiv intraven infus vg/kg cohort vg/kg cohort
vg/kg cohort cohort youngest patient age month month
month time dose continu track within normal age equival develop month post-
treatment across cohort dose-depend sustain reduct csf heparan sulfat seen
lower limit quantit reach patient cohort
treatment-rel seriou advers event sae report
unrat file detail delay initi piii trial aav-bas gt rdeb juli
elevatebio privat announc allianc agreement mgh cell gene therapi juli
passag privat announc appoint new member exec manag team juli
neutral announc mm privat placement common stock warrant juli
compani mention report
page
page
select catalyst genet medicin coverag
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
dcr-phxc initi long-term registr roll-ov studi ph
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report preliminari data phase i/ii studi batten diseas
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
initi phase i/ii trial dmd
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
initi dose phase trial hemophilia
provid updat priorit program sjogren syndrom al wet
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
initi phase i/ii trial
file ind cta pomp diseas
initi trial malign
present top-lin data phase i/iia clinic trial wet
 fc report final analysi phase trial rhgg
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meiragtx replimun solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
initi phase trial recess dystroph epidermolysi bullosa
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
begin patient dose phase trial
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase i/ii trial leukocyt adhes deficiency-i
report initi phase data process fanconi anemia
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi phase i/ii trial parkinson diseas mutat
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end juli vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm solid genet therapytickerratingccm ptupsideclosechang changemc mm arcturu gene editingtickerratingccm ptupsideclosechang changemc mm edita pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
